Tuesday, September 29, 2020
News
NEWS HOME
»
PRESS RELEASES

Terns Pharmaceuticals Announces Completion and Positive Results from Phase 1 Clinical Trial of TERN-201, a SSAO Inhibitor in Development for NASH
  SocialTwist Tell-a-Friend  
   


Date: 30-07-2020 3:13PM
Source: Terns Pharmaceuticals, Inc.
Category: General, Science & Research, Healthcare & Biotechnology, Pharmaceutical
Location: Shanghai, China & Foster City, Calif., United States

Business Wire India

Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat liver disease and cancer, today announced positive results from its completed Phase 1 single ascending dose and multiple ascending dose study of TERN-201, a semicarbazide-sensitive amine oxidase (SSAO) inhibitor, being developed for the treatment of non-alcoholic steatohepatitis (NASH). The data from the first-in-human clinical study of TERN-201 demonstrate that single and multiple oral administrations of TERN-201 were well tolerated with no significant safety findings observed. Each dose level studied showed potent target engagement and achieved near complete inhibition of plasma SSAO activity that was maintained up to one week after single dose or repeat dose administrations of TERN-201.

"Overall, these data suggest TERN-201 is an industry-leading SSAO inhibitor with the potential to be a promising new therapy for NASH and other inflammatory diseases,” said Erin Quirk, M.D., President and Chief Medical Officer of Terns. “These positive data further solidify our approach of building a diverse NASH pipeline and move us closer to our goal of developing safe and effective NASH combination regimens.”

Phase 1 Study Design and Results

The Phase 1 TERN-201 trial was a multiple phase, single- and multiple-ascending dose study in healthy human participants. In the first phase, study volunteers received a single dose of TERN-201 or placebo in ascending dose cohorts. In the second phase of the study, healthy participants received repeat doses of TERN-201 or placebo to 7 or 14 days, also in ascending dose cohorts. The primary endpoint for each phase of the trial was safety and tolerability. Secondary endpoints included pharmacokinetics (PK) and pharmacodynamic (PD) biomarker assessments of SSAO target engagement.

Mean percent of baseline SSAO activity following once daily administration of placebo or TERN-201:

Dose group

Remaining SSAO activity

Placebo
(N=6)

1 mg
7 days
(N=5)

4 mg
7 days
(N=6)

10 mg
14 days
(N=6)

Day 1 (24 hours after first dose)

92.5%

13.8%

4.7%

0%

Day 7 (24 hours after Day 7 dose)

90%

0%

0%

0%


About Semicarbazide-Sensitive Amine Oxidase (SSAO) Inhibition and TERN-201

SSAO, also known as VAP-1 (Vascular Adhesion Protein-1), is a dual-function amine oxidase which increases oxidative stress through the generation of H2O2 and promotes recruitment of white blood cells in the liver, which results in increased oxidative stress, inflammation and hepatic fibrosis. The level of surface SSAO is upregulated in the vasculature of inflamed tissues, and soluble SSAO levels are elevated in patients with NASH. Inhibition of SSAO is believed to have therapeutic benefit for the treatment of NAFLD, NASH and other chronic fibrotic liver diseases. TERN-201 is a potent SSAO inhibitor which provides an additional treatment mechanism for NASH by reducing oxidative stress and recruitment of white blood cells to the liver. TERN-201 is highly specific for SSAO, with a preferential in vitro selectivity index to SSAO over off-target monoamine oxidases (MAO) of >7,000-fold. Certain MAOs could be associated with potential drug-drug interactions in the NASH patient population

About NASH

Non-alcoholic steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease (NAFLD), which is caused by the accumulation of excess fat in the liver. NASH is associated with chronic liver inflammation and liver cell injury, and it can lead to fibrosis, cirrhosis, and eventually liver cancer or liver failure. Global rates of NAFLD and NASH are increasing rapidly, in tandem with rising rates of obesity. There is currently no approved medication for the treatment of NASH.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company that is focused on the discovery and development of medicines for chronic liver disease and cancer. Based in China and the United States, the company is advancing a pipeline of drug candidates for the treatment of non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), and cancer, across multiple modalities. Terns leverages world class expertise in disease biology, medicinal chemistry, and clinical development in order to bring promising new therapies to patients.

For more information, visit www.ternspharma.com and www.ternspharma.com.cn



CONTACTS :

US Media Contact:Margaret Robinson
+1 (415) 690 0084

China Media Contact:
Zhou Zhou
+86 13482103703

More Press Releases

Skyhook Makes Location Accessible Through Smart Feature Phone Integrations

Andersen Global Strengthens Caribbean Presence with Addition of Templar Chambers

Wenatchee Valley College Evaluates IT Environment After Local College Hit with Ransomware

Moody’s Enhances Flagship Moody’s CreditView Platform With ESG Expertise

Sintavia Acquires Two Additional M400-4 Printers from EOS GmbH

Savonix and Fujitsu Connected Technologies Limited Partner to Introduce Savonix Mobile App on Raku-Raku Smartphone F-42A

Application of Forensic DNA Technology Critical to Deter Sexual Predators as Rape Complaints Reach Pre-Pandemic Levels

Oasis Fertility’s Groundbreaking Initiative to Beat COVID Apprehensions With IVF @Home

Boehringer Ingelheim invests to further develop the pet care market in China

Three Indian’s Launch Faceless Chat the World’s First App That Turns Facebook or WhatsApp Into an Anonymous Social Network

QuantInsti Celebrates 10 Years of Serving Quant Traders Globally

Toshiba Launches Ultra-Low Current Consumption CMOS Operational Amplifier That Contributes to Longer Operating Hours of Battery-Operated Devices

Corrugated Box Industry in Distress over Rising Kraft Paper Prices and Supply Disruptions

AEA2020: October 27th to 29th Online

Rimini Street Celebrates 15 Years of Delivering Client Success

Ares Management Corporation Names John Knox as Australia & New Zealand Chairman of Ares SSG

UL Launches Bureau of Indian Standards Recognized Heating, Ventilation and Air Conditioning Testing Services for Electronic Controllers

Mavenir acquires ip.access to expand OpenRAN radio portfolio for CSPs and Enterprise Private Networks

PCI Pharma Services Introduces First-of-its-Kind Digital Platform to Provide Clients with Real-Time Supply Chain Data and Analytics

Kissflow Partners with The Digital Workplace for a First-of-Its-Kind Tweetathon on Digital Workplace Day

India Pulses and Grains Association Hosts The IPGA Knowledge Series Webinar on Kharif Crop Outlook for 2020-21 Season

MetLife to Reduce Emissions by 30 Percent and Originate $20 Billion of New Green Investments By 2030

World Tourism Day: Reviving Travel and Tourism Industry in the Post- COVID-19 World

NTT Com Demonstration Test to Link GAIA-X Platform’s “IDS Connector” Technology and SDPF Based on Data Trust®

Dramz Global LLC Announces Its Global Video Streaming App vRockk

Mintel: 41 percent of Young Indian Beer Drinkers Are Willing to Switch to Low or No Alcohol Beer

L&T Technology Services Selected to Support Tenneco DRiV™ Ride Performance Division

 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
INDIA WORLD ASIA
Youth kills 11 pigeons to avenge 'insult...
Pakistan violates ceasefire in J-K's Man...
Four arrested in UP's Sambhal for bettin...
Maoist killed in Chhattisgarh's Bijapur...
Patnaik launches initiative to make Odis...
Teachers in Jharkhand's Dumka turn villa...
More...    
 
 Top Stories
Adam Sandler is up for reuniting wi... 
Valliappa Foundation launches 'Anad... 
'Ishq Subhan Allah' to go off air... 
Amazon sellers expect sales growth ... 
HAL rolls out 300th Dhruv chopper i... 
Amanda Seyfried gives birth to seco... 
MECL starts exploration in Kolar Go... 
Congress misleading farmers on new ...